Virtu Financial LLC Acelrx Pharmaceuticals Inc Transaction History

Virtu Financial LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	SELL	$0.2 - $0.35 $9,418 - $16,482	-47,093 Reduced 39.42%	72,367 $15,000
Q2 2022 Aug 09, 2022	BUY	$0.18 - $0.29 $21,502 - $34,643	119,460 New	119,460 $29,000
Q1 2022 May 17, 2022	SELL	$0.28 - $0.61 $12,437 - $27,095	-44,419 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$0.49 - $1.02 $3,342 - $6,958	6,822 Added 18.15%	44,419 $25,000
Q3 2021 Nov 12, 2021	BUY	$0.93 - $1.51 $34,965 - $56,771	37,597 New	37,597 $38,000

Q2 2021 Sep 17, 2021	SELL	$1.03 - $1.7 $57,471 - $94,856	-55,798 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$1.25 - $2.77 $69,747 - $154,560	55,798 New	55,798 $95,000
Q4 2020 Feb 24, 2021	SELL	$1.18 - $1.98 $107,158 - $179,807	-90,812 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$1.01 - $1.81 $67,038 - $120,138	66,375 Added 271.62%	90,812 $129,000
Q2 2020 Aug 07, 2020	BUY	$1.03 - $1.69 $25,170 - $41,298	24,437 New	24,437 $30,000
Q4 2018 Jan 16, 2019	SELL	$2.13 - $4.8 $42,078 - $94,824	-19,755 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$2.6 - $4.6 $39,039 - $69,069	-15,015 Reduced 43.18%	19,755 $76,000
Q3 2018 Nov 13, 2018	BUY	$2.6 - $4.6 $62,933 - $111,342	24,205 Added 229.11%	34,770 $134,000
Q2 2018 Jul 30, 2018	SELL	$2.13 - $4.2 $37,468 - $73,882	-17,591 Reduced 62.48%	10,565 $36,000
Q2 2018 Jul 30, 2018	SELL	$2.13 - $4.2 $126,355 - $249,152	-59,322 Reduced 67.81%	28,156 $95,000
Q1 2018 May 14, 2018	BUY	$1.7 - $2.35 $48,099 - $66,490	28,294 Added 47.81%	87,478 $184,000
Q4 2017 Feb 09, 2018	BUY	$1.75 - $5.5 $103,572 - $325,512	59,184	59,184 $120,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.